Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • Editorial Board
    • General Statistics
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
    • Information for Advertisers
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • Editor Picks
    • Blogging Stroke
    • AHA/ASA Guidelines and Statements
    • ISC and Nursing Symposium Abstracts
    • Progress and Innovation Award Recipients
    • Acknowledgment of Reviewers
    • Stroke in Women
    • Outstanding Reviewers 2017
  • Resources
    • Online Submission/Peer Review
    • Instructions for Authors
    • → Article Types
    • → General Preparation Instructions
    • → Research Guidelines
    • → How to Submit a Manuscript
    • → Tips for Submission
    • → Links and Forms
    • → Revised Manuscripts
    • Costs to Authors
    • Journal Policies
    • Wolters Kluwer Author Services
    • Early Career Resources
    • Stroke CME
    • Webinar Series
    • Permissions and Rights Q&A
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Facebook
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Stroke

  • My alerts
  • Sign In
  • Join

  • Facebook
  • Twitter
  • Home
  • About this Journal
    • Editorial Board
    • General Statistics
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
    • Information for Advertisers
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • Editor Picks
    • Blogging Stroke
    • AHA/ASA Guidelines and Statements
    • ISC and Nursing Symposium Abstracts
    • Progress and Innovation Award Recipients
    • Acknowledgment of Reviewers
    • Stroke in Women
    • Outstanding Reviewers 2017
  • Resources
    • Online Submission/Peer Review
    • Instructions for Authors
    • → Article Types
    • → General Preparation Instructions
    • → Research Guidelines
    • → How to Submit a Manuscript
    • → Tips for Submission
    • → Links and Forms
    • → Revised Manuscripts
    • Costs to Authors
    • Journal Policies
    • Wolters Kluwer Author Services
    • Early Career Resources
    • Stroke CME
    • Webinar Series
    • Permissions and Rights Q&A
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Emerging Therapies

Nutrition and Stroke Prevention

Marc Fisher, Kennedy Lees, J. David Spence
Download PDF
https://doi.org/10.1161/01.STR.0000236633.40160.ee
Stroke. 2006;37:2430-2435
Originally published August 28, 2006
Marc Fisher
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kennedy Lees
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. David Spence
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Info & Metrics
Loading

Abstract

Nutrition is much more important in prevention of stroke than is appreciated by most physicians. The powerful effects of statin drugs in lowering the levels of fasting cholesterol, combined with an unbalanced focus on fasting lipids (as opposed to postprandial fat and oxidative stress), have led many physicians and patients to believe that diet is relatively unimportant. Because the statins can lower fasting lipids by &50% to 60%, and a low-fat diet only lowers fasting cholesterol by &5% to 10%, this error is perhaps understandable. However, a Cretan Mediterranean diet, which is high in beneficial oils, whole grains, fruits, and vegetables and low in cholesterol and animal fat, has been shown to reduce stroke and myocardial infarction by 60% in 4 years compared with the American Heart Association diet. This effect is twice that of simvastatin in the Scandinavian Simvastatin Survival Study: a reduction of myocardial infarction by 40% in 6 years. Vitamins for lowering of homocysteine may yet be shown to be beneficial for reduction of stroke; a key issue is the high prevalence of unrecognized deficiency of vitamin B12, requiring higher doses of vitamin B12 than have been used in clinical trials to date. Efforts to duplicate with supplementation the evidence of benefit for vitamins E, C, and beta carotene have been largely fruitless. This may be related to the broad combination of antioxidants included in a healthy diet. A Cretan Mediterranean diet is probably more effective because it provides a wide range of antioxidants from fruits and vegetables of all colors.

  • diet
  • nutrition
  • prevention
  • stroke
  • vitamins

Nutrition is much more important in prevention of stroke than is appreciated by most physicians and, paradoxically, perhaps even by most nutritionists. Current issues that warrant discussion in this venue include the intake of animal fat and cholesterol, the Cretan Mediterranean diet, the failure of most studies to show benefit of supplements with antioxidant vitamins such as vitamins E and C, and the current controversy over failure of recent clinical trials to show reduction of stroke and other cardiovascular events by lowering plasma total homocysteine with folate, B6, and B12. A key issue is the recent recognition that vitamin B12 deficiency is much more common in the elderly than is commonly appreciated, and therefore higher doses of B12, and possibly additional therapies to lower homocysteine, may be required to achieve adequate reductions of total homocysteine.

Cholesterol and Animal Fat

The powerful effects of statin drugs in lowering of fasting cholesterol have seduced many patients and physicians into believing that diet is relatively unimportant: Why bother with a low-fat diet, which only lowers fasting cholesterol by &5% to 10%,1 when a pill can reduce fasting cholesterol by 50%2?

The reason that diet is still very important is that the blinkered focus on fasting lipids is inappropriate. Cholesterol is measured in the fasting state to minimize variability of the measurement; however, human beings are only in the fasting state for the last few hours of the night. What affects the endothelium for &18 hours of the day is the postprandial levels of lipids, cholesterol, oxidized cholesterol, and oxidative stress that follow meals containing trans fats, animal fat,3 or glucose.4 Diet is therefore much more important than would be predicted by effects on fasting lipids.5

A key problem with current dietary recommendations in North America is a failure to distinguish between kinds of fat and between red meat and poultry and fish. The mantra that “fat is bad” has led to a reduction of fat intake and a corresponding increase in carbohydrate intake, with harmful effects on cardiovascular disease and stroke risk.6 Willett and Stampfer7 indicate in an important review that standard dietary recommendations for low intake of fat arose from thin air, driven by a misplaced desire to simplify, and need to be corrected.

There is increasing evidence that postprandial fats and oxidative stress are as important or more important than fasting lipids.8,9 A high-fat meal impairs endothelial function for several hours,10 and this effect can be mitigated by pretreatment with vitamins C and E,11 indicating that oxidative stress from free radicals is an important contributor to the endothelial dysfunction from high-fat meals.

Carluccio et al12 found a direct antiatherosclerotic effect of oleic acid in endothelial cells. Tsimikas et al13 showed that subjects consuming an American diet had monocyte adhesion and chemotaxis induced by LDL, in contrast to subjects on a normal Greek diet. This effect could be reversed by oleic acid supplementation in subjects on the American diet.

Dietary intake of cholesterol probably is important. The National Cholesterol Education Program (NCEP) dietary guidelines specified a daily cholesterol intake <300 mg/d for low-risk and <200 mg/d for high-risk vascular disease candidates.14 A single egg yolk contains 275 mg of cholesterol, as much as an 8-ounce steak, and therefore it is difficult to understand how dieticians in our vascular wards can continue to advise patients that an intake of 3 eggs per week is acceptable. There is evidence that egg yolks should not be consumed by patients at risk of vascular disease.

Ginsberg et al15showed a dose-response relationship between intake of eggs and increases in plasma cholesterol. Hu et al found that in diabetics, a group with a level of vascular risk equivalent to that of coronary survivors,16 consumption of 1 egg per day was associated with a doubling of coronary risk compared with <1 egg per week.17 It may be that this relates to dietary intake of oxidized cholesterol. Levy et al18 showed that an egg per day only raises levels of LDL cholesterol by 10% but increased LDL oxidation by 34%.

In the Indo-Mediterranean Diet Study, discussed below, the intake of cholesterol in the intervention arm was only 125 mg/d. A single egg yolk thus contains more than twice the daily intake of cholesterol achieved in that diet; so does an 8-ounce steak. A diet suitable for patients with vascular disease should therefore include no egg yolks and much less animal flesh, of any color, than North Americans are used to consuming. (The cholesterol content of all kinds of animal flesh is very similar; the emphasis on avoidance of red meat is based on the effects on fasting lipids of saturated fat, which is higher in red meat.)

Benefits of a Mediterranean Diet

The Ornish regression diet, together with other lifestyle changes, has been shown to regress coronary disease.19 However, it is very difficult for patients to persist with it. Among >16 000 patients with vascular disease that I have followed, only 2 were able to persist with the Ornish diet. A more palatable and acceptable diet is a Mediterranean diet, which is high in beneficial oils (from olive, canola, and fish), high in vitamins and antioxidants, and low in cholesterol, trans fats, and harmful animal fat. A recent Japanese prospective study with 477 325 person-years of follow-up showed a 37% reduction of coronary disease when the highest versus lowest quartiles of fish intake were compared.20

A Mediterranean diet has been shown to improve endothelial function in hyperlipidemic men,21 perhaps in part because it reduces plasma lipid peroxidation.22 Vogel et al23 found that the components of a Mediterranean diet that were responsible for this benefit appeared to be antioxidant-rich foods, including vegetables, fruits, balsamic vinegar, and omega-3–rich fish and canola oil.

There is epidemiological evidence that people who follow a Mediterranean diet are at much lower risk of cardiovascular events.24,25 A Mediterranean diet has also been shown to improve endothelial function and reduce insulin resistance.26

More importantly, there is strong evidence from randomized clinical trials that a Cretan Mediterranean diet is much more effective at reducing vascular events than the diet recommended by the NCEP and the American Heart Association.

Clinical Trials With the Cretan Mediterranean Diet

Two important studies have shown that a Mediterranean diet significantly reduced vascular events compared with a usual Western diet.

In the Lyon Diet Heart Study, 423 survivors of myocardial infarction (MI) were randomized to a “prudent Western diet” amounting to a Step 1 NCEP diet14 or to a Mediterranean diet from Crete. This diet was low in cholesterol, low in animal fat, and high in olive oil, canola oil, fruits, and vegetables; canola margarine was substituted for butter. The proportion of calories from fat was the same (&30%) in the 2 diets, but the Mediterranean diet provided a significant reduction in dietary cholesterol and a significant increase of beneficial oils such as α-linolenic acid as opposed to the animal fats of the prudent Western diet. The patients assigned to the Mediterranean diet27 had a 60% reduction in cardiac death and MI over 4 years (P=0.0001) compared with the prudent Western diet. Importantly, there was no difference in alcohol consumption between the 2 diets.

This reduction in MI and death was twice that achieved by simvastatin in the Scandinavian Simvastatin Survival Study (a reduction of coronary risk by 40% over 6 years).28 Importantly, this benefit was achieved without any difference in fasting lipids between the 2 groups. It seems very likely that the benefit was attributable to reduction of postprandial fat, as well as the increased intake of antioxidants and other beneficial constituents of the Mediterranean diet. Whole grains, in addition to antioxidants and fiber, contain phytoestrogens, which may have beneficial effects on arteries.29 Flax lignans, for example, are potent phytoestrogens.30

These results have been replicated in a study of 1000 patients with coronary artery disease in India. Even though 60% of patients were already vegetarian, a Mediterranean version of the Indian diet reduced coronary and stroke events by half in 2 years, compared with an Indian version of a NCEP Step II diet.31 This was achieved by substituting beneficial oils such as mustard oil or soya oil for harmful fats, with an increase of fruits, vegetables, walnuts, almonds, and whole grains, and a reduction of cholesterol intake to 125 mg/d. Although there has been some concern about the validity of the Indo-Mediterranean diet study,32 an investigation by Berry indicated that despite some problems with record keeping, the results did not appear to be fabricated.33

Beneficial Effects of Antioxidant Vitamins?

A single high-fat meal has been shown to impair endothelial function for several hours,10 and this effect can be reduced by pretreatment with vitamins C and E.11 A Mediterranean diet has been shown to improve endothelial function in hyperlipidemic men.21 A Mediterranean diet has a higher content of antioxidants and significantly lower indices of plasma lipid peroxidation.22 Vogel et al23 studied the effect of components of the Mediterranean diet on endothelial function and found that the beneficial components appeared to be antioxidant-rich foods, including vegetables, fruits, balsamic vinegar, and omega-3–rich fish and canola oil.

Antioxidant vitamins may reduce vascular disease by reducing harmful effects of free radicals.34,35 Oxidation of LDL is thought to be important in atherosclerosis because oxidized LDL is chemotactic to monocytes, stimulates binding of monocytes to the endothelium, traps monocytes in the subendothelial space, and is cytotoxic to vascular cells; it is actively taken up by scavenger receptors on macrophages in the subintima to form foam cells.36 Antioxidants such as probucol and various dietary antioxidants are antiatherosclerotic in animal models and human angiographic studies,37 and epidemiological evidence indicates that high intake and high blood levels of antioxidants, particularly vitamin E, may be protective.36,38

A clinical trial in coronary patients showed reduced vascular death and nonfatal coronary events, although cardiovascular mortality was not reduced.39 In the Womens’ Health Initiative study, vitamin E had no beneficial effects.40 Meta-analysis showed no benefit, and possible harm, from high-dose supplements of vitamin E.41 In the Heart Outcomes Prevention Evaluation (HOPE) trial, vitamin E had no beneficial effects and appeared to increase the risk of heart failure.42 A recent pooled analysis of vitamins and antioxidants showed a small cardiovascular benefit of vitamin C.43 Confusion in this area may result from the need to combine vitamins: vitamin E forms the tocopheryl radical, which may require detoxification by other antioxidants such as vitamin C; Salonen et al44 hypothesized that this effect accounted for their finding of reduced progression of intima-media thickness by combined vitamin E and slow-release vitamin C.

This point raises a general principle that a diet high in antioxidant vitamins may be more beneficial than taking supplementary vitamins and antioxidants because of the combined effects of antioxidants.45 Fruits and vegetables often get their color and flavor from antioxidants: beta carotene in carrots; lycopene in tomatoes, strawberries, and watermelon; resveratrol in grape juice and red wine; and anthocyanins in blueberries. Naringin is the color and flavor of grapefruit; naringin is similar to hesperitin from orange juice and genistein from soy; all of these have beneficial anticancer effects and potential cardiovascular benefits.46–48 A useful slogan in this regard is that “we should eat fruits and vegetables of all colors.”

An exception to this principle may be the use of B vitamins for lowering of homocysteine.

B Vitamins for Lowering of Homocysteine

Despite recent reports of studies showing no reduction of stroke or MI by vitamin therapy for lowering of plasma total homocysteine,49–51 it may be too early to discard the hypothesis that treatment with folate, vitamin B6, and vitamin B12 may reduce stroke and other cardiovascular events. Indeed, the HOPE-2 trial showed a significant reduction of stroke and acute coronary syndrome. There is a strong, independent, and graded risk of elevated total homocysteine,52,53 and many mechanisms provide a strong rationale for lowering of homocysteine: High levels of total homocysteine increase thrombosis,54 impair endothelial function,55–57 and increase oxidative stress.58–60 Treatment to lower total homocysteine with folate, B6, and B12 reverses many of these effects and has other benefits, including reducing Lp(a) and fibrinogen,61 halting the progression of carotid plaque in patients whose plaque was progressing despite treatment of traditional risk factors,62,63 reducing progression of peripheral vascular disease,64 and, in 1 study, reducing restenosis in coronary angioplasty.65 A contrary study, which did not show benefit of vitamin therapy in coronary angioplasty, used a much smaller dose of B12 (40 versus 400 ìg/d).66

This discrepancy raises the issue of unrecognized deficiency of vitamin B12 in the elderly and its relationship to failure of B vitamin therapy in lowering of homocysteine. The Vitamin Intervention for Stroke Prevention (VISP) trial, which showed no reduction of stroke, coronary events, or vascular death in a comparison of high-dose vitamins with low-dose vitamins, faced a number of challenges. Folate fortification of grain products in North America coincided with the start of the trial, and in the face of folate fortification, the key determinant of plasma homocysteine is vitamin B12.67 Both treatment arms received a multiple vitamin tablet containing the usual doses of many vitamins, with either a low or high dose of folate, B6, and B12. Unfortunately, the low-dose arm received the recommended daily intake of B12 (6 ìg), and the high-dose arm received only 400 ìg of B12. We thought that we were using a generous dose of B12 in the high-dose arm, but a subsequent dose-response study in people aged >65 years with serum B12 <212 pmol/L showed that elderly subjects require much higher doses, of 1000 μg/d or more.68 In both treatment arms, patients with low levels of B12 received injections of B12 to avoid subacute combined degeneration of the spinal cord.

In a recent efficacy analysis of the VISP trial, patients capable of responding to the study vitamin were found to have a significant reduction of stroke, death, and coronary disease, and B12 status at the beginning of the trial was a significant determinant of response.69

Vitamin B12 deficiency is much more common in the elderly than is usually recognized because many factors are involved in absorption of B12, all of which may go wrong. The conceptual problem for many physicians is the meaning of the word normal. Most biochemistry laboratories report a “normal” or “reference” range based on the mean ±2 SD. Thus, by definition, only the top 2.5% and the bottom 2.5% of the population are abnormal. This statistical definition of normality results in a “normal” range for serum B12 of &160 to 600 pmol/L, and most physicians think that if the serum B12 level is in the normal range, then it is adequate. However, when adequacy of B12 is assessed in metabolic terms, ie, the level of B12 sufficient to prevent an elevation of methylmalonic acid >271 nmol/L or homocysteine >14 ìmol/L in folate-replete patients, then a much higher proportion of the population is identified as deficient in B12. In the Framingham Study, 40% of the elderly had B12 levels <258 pmol/L, and 12% were B12 deficient. Andres et al70 found that 20% of the elderly are B12 deficient. In my Stroke Prevention Clinic, the “normal” range is substantially lower than in a general population (Figure). A previously unpublished analysis of the database used for the study by Robertson et al67 from our clinic revealed a prevalence of B12 deficiency defined metabolically as above, by tertiles of age, of 12% below age 50 years, 13% between ages 50 and 71 years, and 30% at age 71 years or older.

Figure1
  • Download figure
  • Open in new tab
  • Download powerpoint

Serum B12 levels in a stroke prevention clinic.

To successfully reduce total homocysteine to sufficiently low targets may, in the future, require higher doses of B12. As suggested by Loscalzo,71 it may also require other therapies. Promising candidates include betaine72 and thiols.73–75

Conclusion

Diet is much more important for stroke prevention and B12 deficiency is much more common in the elderly than is commonly realized. Patients at risk of stroke should consume a Cretan Mediterranean diet, avoid egg yolks, eat less animal flesh than do most North Americans, and require higher doses of B12, and in the future they may benefit from improved therapies to lower levels of total homocysteine.

Acknowledgments

Disclosures

None.

  • Received May 26, 2006.
  • Accepted June 5, 2006.

References

  1. ↵
    Ginsberg HN, Barr SL, Gilbert A, Karmally W, Deckelbaum R, Kaplan K, Ramakrishnan R, Holleran S, Dell RB. Reduction of plasma cholesterol levels in normal men on an American Heart Association Step 1 diet or a Step 1 diet with added monounsaturated fat. N Engl J Med. 1990; 322: 574–579.
    OpenUrlPubMed
  2. ↵
    Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Davignon J, Erbel R, Fruchart JC, Tardif JC, Schoenhagen P, Crowe T, Cain V, Wolski K, Goormastic M, Tuzcu EM, for the ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006; 295: 1556–1565.
    OpenUrlCrossRefPubMed
  3. ↵
    Dandona P, Mohanty P, Ghanim H, Aljada A, Browne R, Hamouda W, Prabhala A, Afzal A, Garg R. The suppressive effect of dietary restriction and weight loss in the obese on the generation of reactive oxygen species by leukocytes, lipid peroxidation, and protein carbonylation. J Clin Endocrinol Metab. 2001; 86: 355–362.
    OpenUrlCrossRefPubMed
  4. ↵
    Mohanty P, Hamouda W, Garg R, Aljada A, Ghanim H, Dandona P. Glucose challenge stimulates reactive oxygen species (ROS) generation by leucocytes. J Clin Endocrinol Metab. 2000; 85: 2970–2973.
    OpenUrlCrossRefPubMed
  5. ↵
    Spence JD. Fasting lipids: the carrot in the snowman. Can J Cardiol. 2003; 19: 890–892.
    OpenUrlPubMed
  6. ↵
    Oh K, Hu FB, Cho E, Rexrode KM, Stampfer MJ, Manson JE, Liu S, Willett WC. Carbohydrate intake, glycemic index, glycemic load, and dietary fiber in relation to risk of stroke in women. Am J Epidemiol. 2005; 161: 161–169.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    Willett WC, Stampfer MJ. Rebuilding the food pyramid. Sci Am. 2003; 288: 64–71.
    OpenUrlPubMed
  8. ↵
    Steiner G. Triglyceride-rich lipoproteins and atherosclerosis, from fast to feast. Ann Med. 1993; 25: 431–435.
    OpenUrlPubMed
  9. ↵
    Gronholdt ML, Nordestgaard BG, Nielsen TG, Sillesen H. Echolucent carotid artery plaques are associated with elevated levels of fasting and postprandial triglyceride-rich lipoproteins. Stroke. 1996; 27: 2166–2172.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    Vogel RA, Corretti MC, Plotnick GD. Effect of a single high-fat meal on endothelial function in healthy subjects. Am J Cardiol. 1997; 79: 350–354.
    OpenUrlCrossRefPubMed
  11. ↵
    Plotnick GD, Corretti MC, Vogel RA. Effect of antioxidant vitamins on the transient impairment of endothelium-dependent brachial artery vasoactivity following a single high-fat meal. JAMA. 1997; 278: 1682–1686.
    OpenUrlCrossRefPubMed
  12. ↵
    Carluccio MA, Massaro M, Bonfrate C, Siculella L, Maffia M, Nicolardi G, Distante A, Storelli C, De Caterina R. Oleic acid inhibits endothelial activation: a direct vascular antiatherogenic mechanism of a nutritional component in the Mediterranean diet. Arterioscler Thromb Vasc Biol. 1999; 19: 220–228.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    Tsimikas S, Philis-Tsimikas A, Alexopoulos S, Sigari F, Lee C, Reaven PD. LDL isolated from Greek subjects on a typical diet or from American subjects on an oleate-supplemented diet induces less monocyte chemotaxis and adhesion when exposed to oxidative stress. Arterioscler Thromb Vasc Biol. 1999; 19: 122–130.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    Adult Treatment Panel III. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. Circulation. 2002; 106: 3143–3421.
    OpenUrlFREE Full Text
  15. ↵
    Ginsberg HN, Karmally W, Siddiqui M, Holleran S, Tall AR, Rumsey SC, Deckelbaum RJ, Blaner WS, Ramakrishnan R. A dose-response study of the effects of dietary cholesterol on fasting and postprandial lipid and lipoprotein metabolism in healthy young men. Arterioscler Thromb. 1994; 14: 576–586.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998; 339: 229–234.
    OpenUrlCrossRefPubMed
  17. ↵
    Hu FB, Stampfer MJ, Rimm EB, Manson JE, Ascherio A, Colditz GA, Rosner BA, Spiegelman D, Speizer FE, Sacks FM, Hennekens CH, Willett WC. A prospective study of egg consumption and risk of cardiovascular disease in men and women. JAMA. 1999; 281: 1387–1394.
    OpenUrlCrossRefPubMed
  18. ↵
    Levy Y, Maor I, Presser D, Aviram M. Consumption of eggs with meals increases the susceptibility of human plasma and low-density lipoprotein to lipid peroxidation. Ann Nutr Metab. 1996; 40: 243–251.
    OpenUrlPubMed
  19. ↵
    Ornish d, Schwerwitz LW, Billings JH, Brown SE, Gould KL, Merritt TA, Sparler S, Armstrong WT, Ports TA, Kirkeeide RL, Hogeboom C, Brand RJ. Intensive lifestyle changes for reversal of coronary heart disease. JAMA. 1998; 280: 2001–2007.
    OpenUrlCrossRefPubMed
  20. ↵
    Iso H, Kobayashi M, Ishihara J, Sasaki S, Okada K, Kita Y, Kokubo Y, Tsugane S, for the JPHC Study Group. Intake of fish and n3 fatty acids and risk of coronary heart disease among Japanese: the Japan Public Health Center-Based (JPHC) Study Cohort I. Circulation. 2006; 113: 195–202.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    Fuentes F, Lopez-Miranda J, Sanchez E, Sanchez F, Paez J, Paz-Rojas E, Marin C, Gomez P, Jimenez-Pereperez J, Ordovas JM, Perez-Jimenez F. Mediterranean and low-fat diets improve endothelial function in hypercholesterolemic men. Ann Intern Med. 2001; 134: 1115–1119.
    OpenUrlCrossRefPubMed
  22. ↵
    Mancini M, Parfitt VJ, Rubba P. Antioxidants in the Mediterranean diet. Can J Cardiol. 1995; 11 (suppl G): 105G–109G.
    OpenUrlPubMed
  23. ↵
    Vogel RA, Corretti MC, Plotnick GD. The postprandial effect of components of the Mediterranean diet on endothelial function. J Am Coll Cardiol. 2000; 36: 1455–1460.
    OpenUrlCrossRefPubMed
  24. ↵
    Knoops KT, de Groot LC, Kromhout D, Perrin AE, Moreiras-Varela O, Menotti A, van Staveren WA. Mediterranean diet, lifestyle factors, and 10-year mortality in elderly European men and women: the HALE project. JAMA. 2004; 292: 1433–1439.
    OpenUrlCrossRefPubMed
  25. ↵
    Rimm EB, Stampfer MJ. Diet, lifestyle, and longevity: the next steps? JAMA. 2004; 292: 1490–1492.
    OpenUrlCrossRefPubMed
  26. ↵
    Esposito K, Marfella R, Ciotola M, Di Palo C, Giugliano F, Giugliano G, D’Armiento M, D’Andrea F, Giugliano D. Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA. 2004; 292: 1440–1446.
    OpenUrlCrossRefPubMed
  27. ↵
    de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation. 1999; 99: 779–785.
    OpenUrlAbstract/FREE Full Text
  28. ↵
    Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344: 1383–1389.
    OpenUrlCrossRefPubMed
  29. ↵
    Flight I, Clifton P. Cereal grains and legumes in the prevention of coronary heart disease and stroke: a review of the literature. Eur J Clin Nutr. 2006; May 3 [Epub ahead of print].
  30. ↵
    Spence JD, Thornton T, Muir AD, Westcott ND. The effect of flax seed cultivars with differing content of alpha-linolenic acid and lignans on responses to mental stress. J Am Coll Nutr. 2003; 22: 494–501.
    OpenUrlPubMed
  31. ↵
    Singh RB, Dubnov G, Niaz MA, Ghosh S, Singh R, Rastogi SS, Manor O, Pella D, Berry EM. Effect of an Indo-Mediterranean diet on progression of coronary artery disease in high-risk patients (Indo-Mediterranean Diet Heart Study): a randomized single-blind trial. Lancet. 2002; 360: 1455–1461.
    OpenUrlCrossRefPubMed
  32. ↵
    Horton R. Expression of concern: Indo-Mediterranean Diet Heart Study. Lancet. 2005; 366: 354–356.
    OpenUrlCrossRefPubMed
  33. ↵
    Berry EM. Indo-Mediterranean diet and progression of coronary artery disease. Lancet. 2005; 366: 367.
    OpenUrlCrossRefPubMed
  34. ↵
    Spence JD. Vitamins and antioxidants. In: Bogousslavsky J, ed. Drug Therapy for Stroke Prevention. New York, NY: Taylor & Francis; 2001: 231–252.
  35. ↵
    Brody T. Nutritional Chemistry. 2nd ed. San Diego, Calif: Academic Press; 1999.
  36. ↵
    Diaz MN, Frei B, Vita JA, Keaney JF Jr. Antioxidants and atherosclerotic heart disease. N Engl J Med. 1997; 337: 408–416.
    OpenUrlCrossRefPubMed
  37. ↵
    Tardif JC, Cote G, Lesperance J, Bourassa M, Lambert J, Doucet S, Bilodeau L, Nattel S, de Guise P, for the Multivitamins and Probucol Study Group. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. N Engl J Med. 1997; 337: 365–372.
    OpenUrlCrossRefPubMed
  38. ↵
    Gaziano JM. Vitamin E and cardiovascular disease: observational studies. Ann N Y Acad Sci. 2004; 1031: 280–291.
    OpenUrlCrossRefPubMed
  39. ↵
    Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet. 1996; 347: 781–786.
    OpenUrlCrossRefPubMed
  40. ↵
    Lee IM, Cook NR, Gaziano JM, Gordon D, Ridker PM, Manson JE, Hennekens CH, Buring JE. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women’s Health Study: a randomized controlled trial. JAMA. 2005; 294: 56–65.
    OpenUrlCrossRefPubMed
  41. ↵
    Miller ER III, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005; 142: 37–46.
    OpenUrlCrossRefPubMed
  42. ↵
    Lonn E, Bosch J, Yusuf S, Sheridan P, Pogue J, Arnold JM, Ross C, Arnold A, Sleight P, Probstfield J, Dagenais GR, for the HOPE and HOPE-TOO Trial Investigators. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA. 2005; 293: 1338–1347.
    OpenUrlCrossRefPubMed
  43. ↵
    Knekt P, Ritz J, Pereira MA, O’Reilly EJ, Augustsson K, Fraser GE, Goldbourt U, Heitmann BL, Hallmans G, Liu S, Pietinen P, Spiegelman D, Stevens J, Virtamo J, Willett WC, Rimm EB, Ascherio A. Antioxidant vitamins and coronary heart disease risk: a pooled analysis of 9 cohorts. Am J Clin Nutr. 2004; 80: 1508–1520.
    OpenUrlAbstract/FREE Full Text
  44. ↵
    Salonen RM, Nyyssonen K, Kaikkonen J, Porkkala-Sarataho E, Voutilainen S, Rissanen TH, Tuomainen TP, Valkonen VP, Ristonmaa U, Lakka HM, Vanharanta M, Salonen JT, Poulsen HE. Six-year effect of combined vitamin C and E supplementation on atherosclerotic progression: the Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) Study. Circulation. 2003; 107: 947–953.
    OpenUrlAbstract/FREE Full Text
  45. ↵
    Woodside JV, McCall D, McGartland C, Young IS. Micronutrients: dietary intake v. supplement use. Proc Nutr Soc. 2005; 64: 543–553.
    OpenUrlCrossRefPubMed
  46. ↵
    Kurowska EM, Spence JD, Jordan J, Wetmore S, Freeman DJ, Piche LA, Serratore P. HDL-cholesterol-raising effect of orange juice in subjects with hypercholesterolemia. Am J Clin Nutr. 2000; 72: 1095–1100.
    OpenUrlAbstract/FREE Full Text
  47. ↵
    Borradaile NM, de Dreu LE, Barrett PH, Behrsin CD, Huff MW. Hepatocyte apoB-containing lipoprotein secretion is decreased by the grapefruit flavonoid, naringenin, via inhibition of MTP-mediated microsomal triglyceride accumulation. Biochemistry. 2003; 42: 1283–1291.
    OpenUrlCrossRefPubMed
  48. ↵
    Borradaile NM, Carroll KK, Kurowska EM. Regulation of HepG2 cell apolipoprotein B metabolism by the citrus flavanones hesperetin and naringenin. Lipids. 1999; 34: 591–598.
    OpenUrlCrossRefPubMed
  49. ↵
    Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, Sides EG, Wang CH, Stampfer M. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA. 2004; 291: 565–575.
    OpenUrlCrossRefPubMed
  50. ↵
    Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, McQueen MJ, Probstfield J, Fodor G, Held C, Genest J Jr, for the Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006; 354: 1567–1577.
    OpenUrlCrossRefPubMed
  51. ↵
    Bonaa KH, Njolstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, Wang H, Nordrehaug JE, Arnesen E, Rasmussen K, for the NORVIT Trial Investigators. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006; 354: 1578–1588.
    OpenUrlCrossRefPubMed
  52. ↵
    Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991; 324: 1149–1155.
    OpenUrlCrossRefPubMed
  53. ↵
    Nygård O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 1997; 337: 230–236.
    OpenUrlCrossRefPubMed
  54. ↵
    den Heijer M, Rosendaal FR, Blom HJ, Gerrits WB, Bos GM. Hyperhomocysteinemia and venous thrombosis: a meta-analysis. Thromb Haemost. 1998; 80: 874–877.
    OpenUrlPubMed
  55. ↵
    Bellamy MF, McDowell IF, Ramsey MW, Brownlee M, Bones C, Newcombe RG, Lewis MJ. Hyperhomocysteinemia after an oral methionine load acutely impairs endothelial function in healthy adults. Circulation. 1998; 98: 1848–1852.
    OpenUrlAbstract/FREE Full Text
  56. ↵
    Chambers JC, McGregor A, Jean-Marie J, Kooner JS. Acute hyperhomocysteinaemia and endothelial dysfunction. Lancet. 1998; 351: 36–37.
    OpenUrlPubMed
  57. ↵
    Stamler JS, Osborne JA, Jaraki O, Rabbani LE, Mullins M, Singel D, Loscalzo J. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest. 1993; 91: 308–318.
    OpenUrlCrossRefPubMed
  58. ↵
    Dudman NP, Wilcken DE, Stocker R. Circulating lipid hydroperoxide levels in human hyperhomocysteinemia: relevance to development of arteriosclerosis. Arterioscler Thromb. 1993; 13: 512–516.
    OpenUrlAbstract/FREE Full Text
  59. ↵
    Voutilainen S, Morrow JD, Roberts LJ, Alfthan G, Alho H, Nyyssonen K, Salonen JT. Enhanced in vivo lipid peroxidation at elevated plasma total homocysteine levels. Arterioscler Thromb Vasc Biol. 1999; 19: 1263–1266.
    OpenUrlAbstract/FREE Full Text
  60. ↵
    Zhang F, Slungaard A, Vercellotti GM, Iadecola C. Superoxide-dependent cerebrovascular effects of homocysteine. Am J Physiol. 1998; 274 (pt 2): R1704–R1711.
    OpenUrlPubMed
  61. ↵
    Naruszewicz M, Klinke M, Dziewanowski K, Staniewicz A, Bukowska H. Homocysteine, fibrinogen, and lipoprotein(a) levels are simultaneously reduced in patients with chronic renal failure treated with folic acid, pyridoxine, and cyanocobalamin. Metabolism. 2001; 50: 131–134.
    OpenUrlCrossRefPubMed
  62. ↵
    Peterson JC, Spence JD. Vitamins and progression of atherosclerosis in patients with hyper-homocyst(e)inemia. Lancet. 1998; 351: 263.
    OpenUrlPubMed
  63. ↵
    Hackam DG, Peterson JC, Spence JD. What level of plasma homocyst(e)ine should be treated? Effects of vitamin therapy on progression of carotid atherosclerosis in patients with homocyst(e)ine levels above and below 14mol/L. Am J Hypertens. 2000; 13: 105–110.
    OpenUrlCrossRefPubMed
  64. ↵
    Taylor LM Jr, Moneta GL, Sexton GJ, Schuff RA, Porter JM. Prospective blinded study of the relationship between plasma homocysteine and progression of symptomatic peripheral arterial disease. J Vasc Surg. 1999; 29: 8–19.
    OpenUrlCrossRefPubMed
  65. ↵
    Schnyder G, Roffi M, Pin R, Flammer Y, Lange H, Eberli FR, Meier B, Turi ZG, Hess OM. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med. 2001; 345: 1593–1600.
    OpenUrlCrossRefPubMed
  66. ↵
    Lange H, Suryapranata H, De Luca G, Borner C, Dille J, Kallmayer K, Pasalary MN, Scherer E, Dambrink JH. Folate therapy and in-stent restenosis after coronary stenting. N Engl J Med. 2004; 350: 2673–2681.
    OpenUrlCrossRefPubMed
  67. ↵
    Robertson J, Iemolo F, Stabler SP, Allen RH, Spence JD. Increased importance of vitamin B12 for total homocysteine and carotid plaque in the era of folate fortification of the grain supply. CMAJ. 2005; 172: 1569–1573.
    OpenUrlAbstract/FREE Full Text
  68. ↵
    Rajan S, Wallace JI, Brodkin KI, Beresford SA, Allen RH, Stabler SP. Response of elevated methylmalonic acid to three dose levels of oral cobalamin in older adults. J Am Geriatr Soc. 2002; 50: 1789–1795.
    OpenUrlCrossRefPubMed
  69. ↵
    Spence JD, Bang H, Chambless LE, Stampfer MJ. Vitamin Intervention for Stroke Prevention Trial: an efficacy analysis. Stroke. 2005; 36: 2404–2409.
    OpenUrlAbstract/FREE Full Text
  70. ↵
    Andres E, Loukili NH, Noel E, Kaltenbach G, Abdelgheni MB, Perrin AE, Noblet-Dick M, Maloisel F, Schlienger JL, Blickle JF. Vitamin B12 (cobalamin) deficiency in elderly patients. CMAJ. 2004; 171: 251–259.
    OpenUrlAbstract/FREE Full Text
  71. ↵
    Loscalzo J. Homocysteine trials: clear outcomes for complex reasons. N Engl J Med. 2006; 354: 1629–1632.
    OpenUrlCrossRefPubMed
  72. ↵
    Olthof MR, van VT, Boelsma E, Verhoef P. Low dose betaine supplementation leads to immediate and long term lowering of plasma homocysteine in healthy men and women. J Nutr. 2003; 133: 4135–4138.
    OpenUrlAbstract/FREE Full Text
  73. ↵
    House AA, Eliasziw M, Urquhart BL, Freeman DJ, Spence JD. Dimercaptosuccinic acid for the treatment of hyperhomocysteinemia in hemodialysis patients: a placebo-controlled, double-blind, randomized trial. Am J Kidney Dis. 2004; 44: 689–694.
    OpenUrlCrossRefPubMed
  74. ↵
    Urquhart BL, House AA, Cutler MJ, Spence JD, Freeman DJ. Thiol exchange: an in vitro assay that predicts the efficacy of novel homocysteine lowering therapies J Pharm Sci. 2006; Jun 22 [Epub ahead of print].
  75. ↵
    Pendyala L, Schwartz G, Smith P, Zdanowicz J, Murphy M, Hausheer F. Modulation of plasma thiols and mixed disulfides by BNP7787 in patients receiving paclitaxel/cisplatin therapy. Cancer Chemother Pharmacol. 2003; 51: 376–384.
    OpenUrlPubMed
View Abstract

Jump to

  • Article
    • Abstract
    • Cholesterol and Animal Fat
    • Benefits of a Mediterranean Diet
    • Clinical Trials With the Cretan Mediterranean Diet
    • Beneficial Effects of Antioxidant Vitamins?
    • B Vitamins for Lowering of Homocysteine
    • Conclusion
    • Acknowledgments
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters
Back to top
Previous ArticleNext Article

This Issue

Stroke
September 2006, Volume 37, Issue 9
  • Table of Contents
Previous ArticleNext Article

Jump to

  • Article
    • Abstract
    • Cholesterol and Animal Fat
    • Benefits of a Mediterranean Diet
    • Clinical Trials With the Cretan Mediterranean Diet
    • Beneficial Effects of Antioxidant Vitamins?
    • B Vitamins for Lowering of Homocysteine
    • Conclusion
    • Acknowledgments
    • References
  • Figures & Tables
  • Info & Metrics

Article Tools

  • Print
  • Citation Tools
    Nutrition and Stroke Prevention
    Marc Fisher, Kennedy Lees and J. David Spence
    Stroke. 2006;37:2430-2435, originally published August 28, 2006
    https://doi.org/10.1161/01.STR.0000236633.40160.ee

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  •  Download Powerpoint
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Stroke.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Nutrition and Stroke Prevention
    (Your Name) has sent you a message from Stroke
    (Your Name) thought you would like to see the Stroke web site.
  • Share on Social Media
    Nutrition and Stroke Prevention
    Marc Fisher, Kennedy Lees and J. David Spence
    Stroke. 2006;37:2430-2435, originally published August 28, 2006
    https://doi.org/10.1161/01.STR.0000236633.40160.ee
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Subjects

  • Epidemiology, Lifestyle, and Prevention
    • Secondary Prevention
  • Stroke
    • Cerebrovascular Disease/Stroke

Stroke

  • About Stroke
  • Instructions for Authors
  • Stroke CME
  • Guidelines and Statements
  • Meeting Abstracts
  • Permissions
  • Journal Policies
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Editorial Office Address:
200 5th Avenue
Suite 1020
Waltham, MA 02451
email: stroke@strokeahajournal.org

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured